Should cT2 esophageal cancer get neoadjuvant treatment before surgery?

Affiliations

¹ Department of Hematology, Medical Oncology and Tumor Immunology, Augustenburger Platz 1, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
² Charité Comprehensive Cancer Center, Charitéplatz 1, 10117 Berlin, Germany.

Editorial

Peter Thuss-Patience et al. J Thorac Dis. 2017 Sep.

. 2017 Sep;9(9):2819-2823.

doi: 10.21037/jtd.2017.08.143.

¹ Department of Hematology, Medical Oncology and Tumor Immunology, Augustenburger Platz 1, Charité Universitätsmedizin Berlin, 13353 Berlin, Germany.
² Charité Comprehensive Cancer Center, Charitéplatz 1, 10117 Berlin, Germany.

No abstract available

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

Role of neoadjuvant treatment in clinical T2N0M0 oesophageal cancer: results from a retrospective multi-center European study.
Markar SR, Gronnier C, Pasquer A, Duhamel A, Beal H, Théreaux J, Gagnière J, Lebreton G, Brigand C, Meunier B, Collet D, Mariette C; FREGAT working group – FRENCH – AFC. Markar SR, et al. Eur J Cancer. 2016 Mar;56:59-68. doi: 10.1016/j.ejca.2015.11.024. Epub 2016 Jan 23. Eur J Cancer. 2016. PMID: 26808298

1. Lagergren J, Smyth E, Cunningham D, et al. Oesophageal cancer. Lancet 2017. [Epub ahead of print]. 10.1016/S0140-6736(17)31462-9 - DOI - PubMed
1. Ychou M, Boige V, Pignon JP, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-21. 10.1200/JCO.2010.33.0597 - DOI - PubMed
1. Al-Batran SE, Homann N, Schmalenberg H, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4-AIO): A multicenter, randomized phase 3 trial. J Clin Oncol 2017;35:4004.
1. van Hagen P, Hulshof MC, van Lanschot JJ, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med 2012;366:2074-84. 10.1056/NEJMoa1112088 - DOI - PubMed
1. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 2015;16:1090-1098. 10.1016/S1470-2045(15)00040-6 - DOI - PubMed